Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose-mesenchymal transformation.

Wang JH., Zheng YQ., Qian ZY., Pan YQ., Tian T., Duan XT.

Prospective Study, published in Nat Cell Biol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Nat Cell Biol (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41714703
PMCID
PMC12992116
DOI
10.1038/s41556-026-01885-0
Citations
5

Abstract (original English)

Although peritumoural visceral adipose tissue (tVAT) is anatomically close to tumours such as colorectal cancer, the immune landscape of this tissue and its functional contribution to tumour immunity remain poorly defined. Here, we performed single-cell RNA analysis on the tVAT from patients with colorectal cancer to map its immune landscape and observed that tVAT exhibited a highly immune-infiltrated microenvironment enriched with lymphocytes, especially tumour-specific CD8⁺ T cells. Mechanistically, tVAT competes with the tumour for these immunocytes by activating the CXCL12-CXCR4 axis to promote tumour immune escape. Moreover, tumour-derived factors induce an adipose-mesenchymal transformation process where the adipose stromal cells trans-differentiated into adipose-derived cancer-associated fibroblasts, which secrete large amounts of CXCL12 in tVAT. Clinically, targeting adipose-tumour interaction substantially enhances diagnostic and therapeutic efficacy of anti-PD-1 therapy. These findings offer an understanding of the dynamic crosstalk between tVAT and tumour immune escape, highlighting the tVAT as a potential target for cancer immunotherapy.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansColorectal NeoplasmsChemokine CXCL12Tumor MicroenvironmentAnimalsReceptors, CXCR4Tumor EscapeCancer-Associated FibroblastsCD8-Positive T-LymphocytesIntra-Abdominal Fat

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.